MedTrace Logo

Restoration of Reaching and Grasping Function in Individuals With Spinal Cord Injury Using MyndMove® Neuromodulation Therapy

NCT03439319 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2022-07-18

No results posted yet for this study

Summary

A two-arm, parallel group, multicentre, single-blind, randomized controlled trial comparing electrical neuromodulation delivered by MyndMove® therapy to intensive upper-limb conventional therapy in the treatment of patients with moderate to severe motor impairment to their arms and hands from an incomplete, traumatic spinal cord injury.

Conditions

  • Spinal Cord Injuries
  • Trauma, Nervous System

Interventions

DEVICE

MyndMove®

This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function

OTHER

Conventional Therapy

Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.

Sponsors & Collaborators

  • U.S. Army Medical Research Acquisition Activity

    collaborator FED

  • United States Department of Defense

    collaborator FED

  • Programs for Assessment of Technology in Health Research Institute

    collaborator OTHER

  • McMaster University

    collaborator OTHER

  • MyndTec Inc.

    lead INDUSTRY

Principal Investigators

  • Steve Plymale · MyndTec Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-03
Primary Completion
2022-02-28
Completion
2022-03-31
FDA Device
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03439319 on ClinicalTrials.gov